Merck moves into mRNA space with Moderna alliance

Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (scripintelligence.com, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).

Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (scripintelligence.com, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip